TILDIEM Modified-release tablets (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Tildiem 60mg Modified-Release Tablets.
Qualitative and quantitative composition
Each tablet contains 60mg of the active substance diltiazem hydrochloride. Also contains 125.5mg of lactose monohydrate and 28mg of hydrogenated castor oil. For a full list of excipients, see section 6.1. ...
Pharmaceutical form
Modified release tablet. White, round, biconvex tablets engraved withTILDIEM 60' or DILT 60 or DTZ 60 on one side.
Therapeutic indications
Prophylaxis and treatment of Angina Pectoris.
Posology and method of administration
Adults The usual dose is one tablet (60mg) three times daily. However, patient responses may vary and dosage requirements can differ significantly between individual patients. If necessary the divided ...
Contraindications
Sick sinus syndrome, 2nd or 3rd degree AV block in patients without a functioning pacemaker. Severe bradycardia (less than 50 beats per minute). Left ventricular failure with pulmonary stasis. Lactation. ...
Special warnings and precautions for use
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Close observation is necessary in patients ...
Interaction with other medicinal products and other forms of interaction
Combination contraindicated for safety reasons Dantrolene (infusion) Lethal ventricular fibrillation is regularly observed in animals when intravenous verapamil and dantrolene are administered concomitantly. ...
Pregnancy and lactation
Pregnancy There are very limited data from the use of diltiazem in pregnant patients. Diltiazem has been shown to have reproductive toxicity (see section 5.3) in certain animal species (rat, mice, rabbit). ...
Effects on ability to drive and use machines
On the basis of reported adverse drug reactions, i.e. dizziness (common), malaise (common), the ability to drive and use machines could be altered. However, no studies have been performed.
Undesirable effects
The following CIOMS frequency rating is used, when applicable: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to ≤1/100); rare (≥1/10,000 to ≤1/1,000); very rare (≤1/10,000); not known ...
Overdose
The clinical effects of acute overdose can involve pronounced hypotension leading to collapse and acute kidney injury, sinus bradycardia with or without isorhythmic dissociation, sinus arrest, atrioventricular ...
Pharmacodynamic properties
Pharmacotherapeutic group: Calcium channel blockers; Benzothiazepine derivatives ATC code: C08DB01 Tildiem is a calcium antagonist. It restricts the slow channel entry of calcium into the cell and so ...
Pharmacokinetic properties
Diltiazem hydrochloride is effective in angina, protecting the heart against ischaemia, vasodilating coronary arteries and reducing myocardial oxygen requirements. It is well tolerated and does not generally ...
Preclinical safety data
Pregnancy Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from 4 to 6 times (depending on species) the upper limit of the optimum dosage range in clinical ...
List of excipients
Lactose monohydrate Macrogol 6000 Hydrogenated castor oil Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
PVC/foil blister packs of 90 and 100 tablets. Securitainers, polypropylene body with polyethylene cap containing 50, 100 and 500 tablets. Not all pack sizes may be marketed.
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK or trading as: Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Marketing authorization number(s)
PL 04425/0640
Date of first authorization / renewal of the authorization
Date of first authorisation: 8 March 1984 Date of latest renewal: 23 September 2005
Date of revision of the text
18 March 2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
